Individual pituitary neuropeptides do not recapitulate the effects of repository corticotropin (Acthar®) on human B cells in vitro

J Neuroimmunol. 2021 Apr 15;353:577522. doi: 10.1016/j.jneuroim.2021.577522. Epub 2021 Feb 12.

Abstract

Repository corticotropin injection (RCI), a complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides, has been found to suppress key aspects of gene expression and cellular function in human B lymphocytes in vitro. The present studies reveal that neither individual POMC peptides (α-MSH, ACTH1-39, ACTH1-24, β-endorphin) nor other related pituitary neuropeptides are sufficient to elicit these effects, even though specific receptors capable of transmitting signals from these peptides are expressed by human B cells. RCI's direct effects on human B cells may require complementary signals from multiple components of the preparation.

Keywords: Adrenocorticotropic hormone; B lymphocytes; Immunity; Proopiomelanocortin.

MeSH terms

  • Adult
  • Aged
  • Animals
  • B-Lymphocytes / drug effects*
  • Cells, Cultured
  • Female
  • Humans
  • In Vitro Techniques
  • Male
  • Middle Aged
  • Neuropeptides / pharmacology*
  • Pituitary Hormones / pharmacology*
  • Swine
  • Young Adult

Substances

  • Neuropeptides
  • Pituitary Hormones